Marie-Therése Crafoord

Marie-Therése Crafoord

Auto-generated profile, based on publicly available information

Marie-Therése Crafoord

Department of Clinical Science and Education Södersjukhuset Karolinska Institutet Stockholm Sweden

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MCMarie-Therése Crafoord
Marie-Therése Crafoord
MFMaria Fjell
Maria Fjell
KSKay Sundberg
Kay Sundberg
MNMarie Nilsson
Marie Nilsson
ALAnn Langius-Eklöf
Ann Langius-Eklöf
Background: Using mobile technology for symptom management and self-care can improve patient-clinician communication and clinical outcomes in patients with cancer. The interactive app Interaktor has been shown to reduce symptom burden during cancer treatment. It includes symptom assessment, an alert system for contact with health care professionals, access to self-care advice, and visualization of symptom history. It is essential to understand how digital interventions operate; one approach is to examine engagement by assessing usage and exploring user experiences. Actual usage in relation to the intended use—adherence—is an essential factor of engagement. Objective: This study aimed to describe engagement with the Interaktor app among patients with breast or prostate cancer during treatment. Methods: Patients from the intervention groups of two separate randomized controlled trials were included: patients with breast cancer receiving neoadjuvant chemotherapy (n=74) and patients with locally advanced prostate cancer receiving treatment with radiotherapy (n=75). The patients reported their symptoms daily. Sociodemographic and clinical data were obtained from baseline questionnaires and medical records. Logged data usage was retrieved from the server and analyzed descriptively and with multiple regression analysis. Telephone interviews were conducted with patients about their perceptions of using the app and analyzed using content analysis. Results: The median adherence percentage to daily symptom reporting was 83%. Most patients used the self-care advice and free text message component. Among the patients treated for breast cancer, higher age predicted a lower total number of free text messages sent (P=.04). Among the patients treated for prostate cancer, higher age (P=.01) and higher education level (P=.04), predicted an increase in total views on self-care advice, while higher comorbidity (P=.004) predicted a decrease in total views on self-care advice. Being married or living with a partner predicted a higher adherence to daily symptom reporting (P=.02). Daily symptom reporting created feelings of having continuous contact with health care professionals, being acknowledged, and safe. Being contacted by a nurse after a symptom alert was considered convenient and highly valued. Treatment and time-related aspects influenced engagement. Daily symptom reporting was perceived as particularly meaningful at the beginning of treatment. Requests were made for advice on diet and psychological symptoms, as well as for more comprehensive and detailed information as the patient progressed through treatment. Conclusions: Patient engagement in the interactive app Interaktor was high. The app promoted patient participation in their care through continuous and convenient contact with health care professionals. The predictive ability of demographic variables differed between patient groups, but higher age and a higher educational level predicted usage of specific app functions for both patient groups. Patients’ experience of relevance and interactivity influenced their engagement positively.

4 July 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ALAnn Langius-Eklöf
Ann Langius-Eklöf
MCMarie-Therése Crafoord
Marie-Therése Crafoord
MCMats Christiansen
Mats Christiansen
MFMaria Fjell
Maria Fjell
KSKay Sundberg
Kay Sundberg
Cancer patients are predominantly treated as out-patients and as they often experience difficult symptoms and side effects it is important to facilitate and improve patient-clinician communication to support symptom management and self-care. Although the number of projects within supportive cancer care evaluating mobile health is increasing, few evidence-based interventions are described in the literature and thus there is a need for good quality clinical studies with a randomised design and sufficient power to guide future implementations. An interactive information and communications technology platform, including a smartphone/computer tablet app for reporting symptoms during cancer treatment was created in collaboration with a company specialising in health care management. The aim of this paper is to evaluate the effects of using the platform for patients with breast cancer during neo adjuvant chemotherapy treatment and patients with locally advanced prostate cancer during curative radiotherapy treatment. The main hypothesis is that the use of the platform will improve clinical management, reduce costs, and promote safe and participatory care. The study is a prospective, randomised, controlled trial for each patient group and it is based on repeated measurements. Patients are consecutively included and randomised. The intervention groups report symptoms via the app daily, during treatment and up to three weeks after end of treatment, as a complement to standard care. Patients in the control groups receive standard care alone. Outcomes targeted are symptom burden, quality of life, health literacy (capacity to understand and communicate health needs and promote healthy behaviours), disease progress and health care costs. Data will be collected before and after treatment by questionnaires, registers, medical records and biomarkers. Lastly, participants will be interviewed about participatory and meaningful care. Results will generate knowledge to enhance understanding about how to develop person-centred care using mobile technology. Supporting patients’ involvement in their care to identify problems early, promotes more timely initiation of necessary treatment. This can benefit patients treated outside the hospital setting in regard to maintaining their safety. June 12 2015 NCT02477137 (Prostate cancer) and June 12 2015 NCT02479607 (Breast cancer).

11 March 2025 in JMIR Cancer
Verified
Journal Article
Open access
MCMarie-Therése Crafoord
Marie-Therése Crafoord
JEJoakim Ekstrand
Joakim Ekstrand
KSKay Sundberg
Kay Sundberg
MNMarie I Nilsson
Marie I Nilsson
MFMaria Fjell
Maria Fjell
ALAnn Langius-Eklöf
Ann Langius-Eklöf
Background: Digital interventions for supportive care during cancer treatment incorporating electronic patient-reported outcomes (ePROs) can enhance early detection of symptoms and facilitate timely symptom management. However, economic evaluations are needed. Objective: This study aims to conduct a cost-utility analysis of an app for ePRO and interactive support from the perspective of the payer (Region Stockholm Health Care Organization) and to explore its impact on patient health care utilization and costs. Methods: Two open-label randomized controlled trials (RCTs) were conducted, including patients undergoing neoadjuvant chemotherapy for breast cancer (B-RCT; N=149) and radiotherapy for prostate cancer (P-RCT; N=150), recruited from oncology clinics at 2 university hospitals in Stockholm, Sweden. EORTC QLQ-C30 scores were mapped to EQ-5D-3L to calculate quality-adjusted life years (QALYs). Intervention and implementation costs and health care costs, obtained from an administrative database, were used to calculate incremental cost-effectiveness ratios (ICERs) in 3 ways: including all health care costs (ICERa), excluding nonacute health care costs (ICERb), and excluding health care costs altogether (ICERc). Nonparametric bootstrapping was used to explore ICER uncertainty. Health care costs were analyzed by classifying them as disease-related or acute. Results: In both RCT intervention groups, fewer QALYs were lost compared with the control group (P<.001). In the B-RCT, the mean intervention cost was €92 (SD €2; €1=US $1.03). The mean cost for the intervention and all health care was €36,882 (SD €1032) in the intervention group and €35,427 (SD €959) in the control group (P<.001), with an ICERa of €202,368 (95% CI €152,008-€252,728). The mean cost for the intervention and acute health care was €3585 (SD €480) in the intervention group and €3235 (SD €494) in the control group (P<.001). ICERb was €49,903 (95% CI €37,049-€62,758) and ICERc was €13,213 (95% CI €11,145-€15,281); 22 out of 74 (30%) intervention group patients and 24 out of 75 (32%) of the control group patients required acute inpatient care for fever. In the P-RCT, the mean intervention cost was €43 (SD €0.2). The mean cost for the intervention and all health care was €3419 (SD €739) in the intervention group and €3537 (SD €689) in the control group (P<.001), with an ICERa of –€1,092,136 (95% CI –€3,274,774 to €1,090,502). The mean cost for the intervention and acute health care was €1219 (SD €593) in the intervention group and €802 (SD €281) in the control group (P<.001). ICERb was €745,987 (95% CI –€247,317 to €1,739,292) and ICERc was €13,118 (95% CI –68,468 to €94,704). As many as 10 out of the 75 (13%) intervention group patients had acute inpatient care, with the most common symptom being dyspnea, while 9 out of the 75 (12%) control group patients had acute inpatient care, with the most common symptom being urinary tract infection. Conclusions: ePRO and interactive support via an app generated a small improvement in QALYs at a low intervention cost and may be cost-effective, depending on the costs considered. Considerable variability in patient health care costs introduced uncertainty around the estimates, preventing a robust determination of cost-effectiveness. Larger studies examining cost-effectiveness from a societal perspective are needed. The study provides valuable insights into acute health care utilization during cancer treatment. Trial Registration: ClinicalTrials.gov NCT02479607; https://clinicaltrials.gov/ct2/show/NCT02479607, ClinicalTrials.gov NCT02477137; https://clinicaltrials.gov/ct2/show/NCT02477137 International Registered Report Identifier (IRRID): RR2-10.1186/s12885-017-3450-y

3 February 2023 in CIN: Computers, Informatics, Nursing
Verified
Journal Article
Closed access
MCMarie-Therése Rn Crafoord
Marie-Therése Rn Crafoord
KSKay Rn Sundberg
Kay Rn Sundberg
MNMarie I. Msw Nilsson
Marie I. Msw Nilsson
MFMaria Rn Fjell
Maria Rn Fjell
ALAnn Rn Langius-Eklöf
Ann Rn Langius-Eklöf
The use of symptom management mobile apps can reduce patients' symptom burden during cancer treatment, but the evidence is lacking about their effect on care. Moreover, if patients' health literacy can be improved, it needs to be more rigorously tested. This study aimed to evaluate patients' perceptions of individualized care and health literacy using an interactive app in two randomized trials. Patients undergoing neoadjuvant chemotherapy for breast cancer (N = 149) and radiotherapy for prostate cancer (N = 150) were consecutively included and randomized into one intervention or control group. Outcome measures were Individualized Care Scale, Swedish Functional Health Literacy Scale, and Swedish Communicative and Critical Health Literacy Scale. In the breast cancer trial, no group differences were observed regarding individualized care or health literacy. Most patients had sufficient health literacy levels. In the prostate cancer trial, intervention group patients rated higher perceived individualized care regarding decision control at follow-up than the control group. Less than half had sufficient health literacy levels and intervention group patients significantly improved their ability to seek, understand, and communicate health information. Education level explained significant variance in health literacy in both trials. Using an interactive app can positively affect individualization in care and health literacy skills among patients treated for prostate cancer, although further research is warranted.

28 August 2025 in European Journal of Oncology Nursing
Verified
Journal Article
Open access
NKNazmije Kelmendi
Nazmije Kelmendi
MCMarie-Therése Crafoord
Marie-Therése Crafoord
KSKay Sundberg
Kay Sundberg
ALAnn Langius-Eklöf
Ann Langius-Eklöf
The aim was to evaluate an intervention including an app for symptom monitoring, self-management, and support from a nurse for patients with prostate cancer during radiotherapy. A randomised controlled trial including quantitative and qualitative data. The intervention group (n = 75) used the app, while the control group (n = 75) received only standard care. Primary outcomes were health-related quality of life and symptom burden assessed with the well-validated questionnaires EORTC QLQ-C30 and EORTC QLQ-PR25. Data were collected at baseline (BL), three weeks (FU1), and three months post-treatment (FU2), then analysed by ANCOVA repeated measure. Individual interviews with patients from both groups (n = 37) were performed and analysed by thematic analysis. From BL to FU1, the intervention group experienced an increase in constipation, while the control group showed a decrease (P = 0.01). From BL to FU1 the intervention group experienced less bowel symptoms than the control group (P = 0.01). The interview resulted in two themes: "Perception of care and treatment" and "Passive and active navigation during treatment". Patients from both groups expressed satisfaction with the care they received. Patients in the intervention group described that reporting in the app enhanced their awareness of symptoms; furthermore, it made the patients feel safe and supported. Patients in the control group described insecurity regarding knowing when and where to seek help. The intervention may reduce bowel symptoms and enhance symptom awareness among patients. More research is needed to give evidence of how digital tools can be supportive to patients during radiotherapy for prostate cancer.

1 January 2025 in BioMed Research International
Verified
Journal Article
Open access
MCMarie-Therése Crafoord
Marie-Therése Crafoord
EHElham Hedayati
Elham Hedayati
AJAina Johnsson
Aina Johnsson
Objective: This study evaluates the usability in accordance with EN 62366 of the True Dose kit for capillary blood self‐sampling, to be used to analyze, specify, design, verify, and validate usability as it relates to the safety of medical devices focusing on user performance, experience, and user confidence through a mixed‐methods approach. The usability engineering process is needed to fulfill user interface design requirements as part of product development at True Dose kit. Methods: The study employed a convergent parallel design, integrating quantitative and qualitative data. Twenty‐five participants, recruited through convenience sampling, used the True Dose kit to perform capillary blood self‐sampling. Quantitative data were collected using three key performance metrics—collection of sufficient blood volume, absence of air bubbles, and duration of the self‐sampling process—along with two questionnaires, the System Usability Scale (SUS) and the Test Feedback Questionnaire (TFQ), to comprehensively assess user performance and experience. In contrast, qualitative data were obtained from interviews and free‐text responses. The integration of findings highlighted areas of convergence and divergence between the quantitative and qualitative data. Results: The overall SUS score was 82.70, indicating high usability. However, participants reported challenges with the complexity of instructions and stress associated with blood flow management. Qualitative insights revealed a preference for simplified visual guidance and highlighted the need for precise feedback mechanisms to ensure the correct execution of sampling steps. Despite these challenges, 92% of participants collected the required blood sample, with a median self‐sampling duration of 10.42 min. Conclusion: The True Dose kit demonstrates high usability potential, but improvements in instructional design and stress management are needed to enhance user experience and ensure consistent performance. Trial Registration: EUCT Number: 2024‐514818‐12‐00